Skip to main content
SpringerLink
Log in
Book cover

Cardio-Nephrology pp 329–335Cite as

Revascularization Strategies in CKD: Antiplatelet Therapy, Stent Type, Timing, and Complications of PCI

  • Chapter
  • First Online:

  • 1431 Accesses

Abstract

Accelerated atherosclerosis, coupled with several nontraditional risk factors increases coronary artery disease (CAD) burden in patients with all stages of chronic kidney disease (CKD). Given the complex anatomy, heavy calcific burden, and the brittle bleeding–clotting paradigm in CKD, post-percutaneous coronary interventional outcomes remain inferior in CKD compared to patients with preserved renal function. This chapter will review various aspects of percutaneous coronary intervention (PCI) in patients with CAD and CKD, including outcomes of bare-metal (BMS) versus drug-eluting stents (DES), duration and type of dual antiplatelet therapy, and timing and complications of PCI.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  2. Steinhubl SR, Berger PB, Mann JT 3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–20.

    Article  CAS  PubMed  Google Scholar 

  3. Keltai M, Tonelli M, Mann JF, Sitkei E, Lewis BS, Hawken S, et al. Renal function and outcomes in acute coronary syndrome: impact of clopidogrel. Eur J Cardiovasc Prev Rehabil. 2007;14(2):312–8.

    Article  PubMed  Google Scholar 

  4. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155(4):687–93.

    Article  CAS  PubMed  Google Scholar 

  5. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  CAS  PubMed  Google Scholar 

  6. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.

    Article  PubMed  Google Scholar 

  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  CAS  PubMed  Google Scholar 

  8. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation. 2008;118(16):1626–36.

    Article  CAS  PubMed  Google Scholar 

  9. Kotani J, Awata M, Nanto S, Uematsu M, Oshima F, Minamiguchi H, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol. 2006;47(10):2108–11.

    Article  CAS  PubMed  Google Scholar 

  10. Siddiqi OK, Smoot KJ, Dufour AB, Cho K, Young M, Gagnon DR, et al. Outcomes with prolonged clopidogrel therapy after coronary stenting in patients with chronic kidney disease. Heart. 2015;101(19):1569–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transpl. 2000;15(2):218–23.

    Article  CAS  Google Scholar 

  12. Varela AM, Taniguchi E, Stadler N, Faria-Neto JR, Pecoits-Filho R. Use of intravascular ultrasonography for the characterization of coronary artery disease in patients with chronic kidney disease. J Bras Nefrol. 2011;33(4):413–21.

    Article  PubMed  Google Scholar 

  13. Kato K, Yonetsu T, Jia H, Abtahian F, Vergallo R, Hu S, et al. Nonculprit coronary plaque characteristics of chronic kidney disease. Circ Cardiovasc Imaging. 2013;6(3):448–56.

    Article  PubMed  Google Scholar 

  14. Chan MY, Becker RC, Sim LL, Tan V, Lee CH, Low AF, et al. Reperfusion strategy and mortality in ST-elevation myocardial infarction among patients with and without impaired renal function. Ann Acad Med Singap. 2010;39(3):179–84.

    PubMed  Google Scholar 

  15. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319–25.

    Article  PubMed  Google Scholar 

  16. Charytan DM, Wallentin L, Lagerqvist B, Spacek R, De Winter RJ, Stern NM, et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol. 2009;4(6):1032–43.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART). Circulation. 2009;120(10):851–8.

    Article  CAS  PubMed  Google Scholar 

  18. Aoyama T, Ishii H, Toriyama T, Takahashi H, Kasuga H, Murakami R, et al. Sirolimus-eluting stents vs bare metal stents for coronary intervention in Japanese patients with renal failure on hemodialysis. Circ J. 2008;72(1):56–60.

    Article  PubMed  Google Scholar 

  19. Attallah N, Yassine L, Fisher K, Yee J. Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin Nephrol. 2005;64(6):412–8.

    Article  CAS  PubMed  Google Scholar 

  20. Rubenstein MH, Harrell LC, Sheynberg BV, Schunkert H, Bazari H, Palacios IF. Are patients with renal failure good candidates for percutaneous coronary revascularization in the new device era? Circulation. 2000;102(24):2966–72.

    Article  CAS  PubMed  Google Scholar 

  21. Charytan DM, Garg P, Varma M, Garshick MS, Jeon C, Mauri L. Angiographic characteristics of coronary arterial segments progressing to myocardial infarction in patients with and without chronic kidney disease. Clin Exp Nephrol. 2013;17(2):232–9.

    Article  PubMed  Google Scholar 

  22. Chonchol M, Whittle J, Desbien A, Orner MB, Petersen LA, Kressin NR. Chronic kidney disease is associated with angiographic coronary artery disease. Am J Nephrol. 2008;28(2):354–60.

    Article  PubMed  Google Scholar 

  23. Coskun U, Orta Kilickesmez K, Abaci O, Kocas C, Bostan C, Yildiz A, et al. The relationship between chronic kidney disease and SYNTAX score. Angiology. 2011;62(6):504–8.

    Article  PubMed  Google Scholar 

  24. Kono K, Fujii H, Miyoshi N, Kawamori H, Shite J, Hirata K, et al. Coronary plaque morphology using virtual histology-intravascular ultrasound analysis in hemodialysis patients. Ther Apher Dial. 2011;15(1):44–50.

    Article  PubMed  Google Scholar 

  25. Berger AK, Duval S, Krumholz HM. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol. 2003;42(2):201–8.

    Article  CAS  PubMed  Google Scholar 

  26. Latif F, Kleiman NS, Cohen DJ, Pencina MJ, Yen CH, Cutlip DE, et al. In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. JACC Cardiovasc Interv. 2009;2(1):37–45.

    Article  PubMed  Google Scholar 

  27. Shenoy C, Boura J, Orshaw P, Harjai KJ. Drug-eluting stents in patients with chronic kidney disease: a prospective registry study. PLoS ONE. 2010;5(11):e15070.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Appleby CE, Ivanov J, Lavi S, Mackie K, Horlick EM, Ing D, et al. The adverse long-term impact of renal impairment in patients undergoing percutaneous coronary intervention in the drug-eluting stent era. Circ Cardiovasc Interv. 2009;2(4):309–16.

    Article  PubMed  Google Scholar 

  29. Osorio Gomes V, Blaya P, Lasevitch R, Oliveira D, Hickmann P, Smidt L, et al. Impact of chronic kidney disease on the efficacy of drug-eluting stents: long-term follow-up study. Arq Bras Cardiol. 2011;96(5):346–51.

    Article  PubMed  Google Scholar 

  30. Wanitschek M, Pfisterer M, Hvelplund A, De Servi S, Bertel O, Jeger R, et al. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease. Int J Cardiol. 2013;168(3):2381–8.

    Article  PubMed  Google Scholar 

  31. Tsai TT, Messenger JC, Brennan JM, Patel UD, Dai D, Piana RN, et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: a report from the linked CathPCI Registry-CMS claims database. J Am Coll Cardiol. 2011;58(18):1859–69.

    Article  CAS  PubMed  Google Scholar 

  32. Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation. 2002;106(17):2207–11.

    Article  PubMed  Google Scholar 

  33. Best PJ, Berger PB, Davis BR, Grines CL, Sadeghi HM, Williams BA, et al. Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial. J Am Coll Cardiol. 2004;44(9):1786–91.

    PubMed  Google Scholar 

  34. Das P, Moliterno DJ, Charnigo R, Mukherjee D, Steinhubl SR, Sneed JD, et al. Impact of drug-eluting stents on outcomes of patients with end-stage renal disease undergoing percutaneous coronary revascularization. J Invasive Cardiol. 2006;18(9):405–8.

    PubMed  Google Scholar 

  35. Halkin A, Selzer F, Marroquin O, Laskey W, Detre K, Cohen H. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients. J Invasive Cardiol. 2006;18(12):577–83.

    PubMed  Google Scholar 

  36. Ishio N, Kobayashi Y, Takebayashi H, Iijima Y, Kanda J, Nakayama T, et al. Impact of drug-eluting stents on clinical and angiographic outcomes in dialysis patients. Circ J. 2007;71(10):1525–9.

    Article  PubMed  Google Scholar 

  37. Suzuki K, Inoue N, Matsuo A, Shiono Y, Nakanishi N, Otsuki Y, et al. Limitation on efficacy of sirolimus-eluting stent implantation in patients on hemodialysis. J Cardiol. 2007;49(6):331–6.

    PubMed  Google Scholar 

  38. Sasao H, Hotta D, Maeda T, Saito N, Takagi S, Shimamoto K. Comparison of long-term clinical outcome after sirolimus-eluting stent implantation in patients with and without hemodialysis. Int Heart J. 2007;48(6):689–700.

    Article  PubMed  Google Scholar 

  39. Nakazawa G, Tanabe K, Aoki J, Yamamoto H, Higashikuni Y, Onuma Y, et al. Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheter Cardiovasc Interv. 2007;69(6):808–14.

    Article  PubMed  Google Scholar 

  40. Hassani SE, Chu WW, Wolfram RM, Kuchulakanti PK, Xue Z, Gevorkian N, et al. Clinical outcomes after percutaneous coronary intervention with drug-eluting stents in dialysis patients. J Invasive Cardiol. 2006;18(6):273–7.

    PubMed  Google Scholar 

  41. Vuurmans T, Byrne J, Fretz E, Janssen C, Hilton JD, Klinke WP, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). Heart. 2010;96(19):1538–42.

    Article  PubMed  Google Scholar 

  42. de la Torre-Hernandez JM, Alfonso F, Hernandez F, Elizaga J, Sanmartin M, Pinar E, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51(10):986–90.

    Article  PubMed  Google Scholar 

  43. Miao Y, Yu-Jie Z, Zhi-Jian W, Dong-Mei S, Yu-Yang L, Ying-Xin Z, et al. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents. Catheter Cardiovasc Interv. 2012;80(3):361–7.

    Article  PubMed  Google Scholar 

  44. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–30.

    Article  CAS  PubMed  Google Scholar 

  45. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol. 2007;50(6):501–8.

    Article  CAS  PubMed  Google Scholar 

  46. Choi DH, Park KW, Yang HM, Lee HY, Park JS, Kang HJ, et al. Renal dysfunction and high levels of hsCRP are additively associated with hard endpoints after percutaneous coronary intervention with drug eluting stents. Int J Cardiol. 2011;149(2):174–81.

    Article  PubMed  Google Scholar 

  47. Krasniak A, Drozdz M, Pasowicz M, Chmiel G, Michalek M, Szumilak D, et al. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transpl. 2007;22(2):515–21.

    Article  Google Scholar 

  48. Cuisset T, Frere C, Moro PJ, Quilici J, Pons C, Gaborit B, et al. Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. Thromb Res. 2010;126(5):e400–2.

    Article  CAS  PubMed  Google Scholar 

  49. Htun P, Fateh-Moghadam S, Bischofs C, Banya W, Muller K, Bigalke B, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22(4):627–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104(9):1292–5.

    Article  CAS  PubMed  Google Scholar 

  51. Prada-Delgado O, Estevez-Loureiro R, Calvino-Santos R, Barge-Caballero E, Salgado-Fernandez J, Pinon-Esteban P, et al. Renal insufficiency and vascular complications after primary angioplasty via femoral route Impact of vascular closure devices use. Rev Esp Cardiol (Engl Ed). 2012;65(3):258–64.

    Article  PubMed  Google Scholar 

  52. Aziz EF, Pulimi S, Coleman C, Florita C, Musat D, Tormey D, et al. Increased vascular access complications in patients with renal dysfunction undergoing percutaneous coronary procedures using arteriotomy closure devices. J Invasive Cardiol. 2010;22(1):8–13.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Kaiser Permanente, Los Angeles Medical Center, 1526 Edgemont St, Second Floor, Cardiology, Los Angeles, CA, 90027, USA

    Marwan Y. Qattan

  2. Department of Cardiology and Regional Cardiac Cath Lab, Kaiser Permanente, Los Angeles Medical Center, 4867 Sunset Blvd, 3rd Floor, Rm 3755, Los Angeles, CA, 90027, USA

    Somjot S. Brar

Authors
  1. Marwan Y. Qattan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Somjot S. Brar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Somjot S. Brar .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, Einstein Medical Center, Sidney Kimmel College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA

    Janani Rangaswami

  2. Department of Medicine, Section of Nephrology, University of Illinois at Chicago, Chicago, Illinois, USA

    Edgar V. Lerma

  3. Department of Nephrology Dialysis and Transplantation, International Renal Research Institute, San Bortolo Hospital, Vicenza, Italy

    Claudio Ronco

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Qattan, M.Y., Brar, S.S. (2017). Revascularization Strategies in CKD: Antiplatelet Therapy, Stent Type, Timing, and Complications of PCI. In: Rangaswami, J., Lerma, E., Ronco, C. (eds) Cardio-Nephrology. Springer, Cham. https://doi.org/10.1007/978-3-319-56042-7_31

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56042-7_31

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56040-3

  • Online ISBN: 978-3-319-56042-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation